期刊： CLINICAL DRUG INVESTIGATION, 2023; ()
Background Cilostazol is the only first-line medication for treating intermittent claudication, and the controlled-release (CR) formulation is associa......
期刊： CLINICAL DRUG INVESTIGATION, 2023; 43 (11)
Background and ObjectiveMost evidence suggests that the pharmacokinetics of monoclonal antibodies (mAbs) are not meaningfully altered by patient chara......
期刊： CLINICAL DRUG INVESTIGATION, 2023; 43 (6)
Background and Objective HP501 is a highly selective renal urate transporter 1 (URAT1) inhibitor that is being developed for the treatment of hyperuri......
期刊： CLINICAL DRUG INVESTIGATION, 2023; 43 (6)
Background and ObjectiveThere is an unmet need for a safer anticoagulant since bleeding remains a concern with currently approved anticoagulants. Coag......
期刊： CLINICAL DRUG INVESTIGATION, 2023; ()
Background Dipeptidyl peptidase-4 inhibitors have limited efficacy in improving glycemic control for obese Japanese patients with type 2 diabetes mell......
期刊： CLINICAL DRUG INVESTIGATION, 2023; ()
Background and ObjectiveSpinal muscular atrophy (SMA) is a genetic disorder with limited treatment options. It is crucial to have a comprehensive unde......
期刊： CLINICAL DRUG INVESTIGATION, 2023; 43 (3)
Background and ObjectiveAlthough improving adherence to adjuvant endocrine therapies (AETs) is critical to ensure better patient outcomes, the evidenc......
期刊： CLINICAL DRUG INVESTIGATION, 2023; 43 (2)
Background and Objective The expanding use of botulinum toxin (BoNT) in medical practice demonstrates the need to highlight whether there is adequate ......
期刊： CLINICAL DRUG INVESTIGATION, 2023; 43 (11)
Background and ObjectivesAtezolizumab has demonstrated safety and efficacy in patients with metastatic non-small cell lung cancer (NSCLC) in the IMpow......
期刊： CLINICAL DRUG INVESTIGATION, 2023; 43 (11)
Background and Objective Acitretin has long-lasting teratogenic properties. Therefore, pregnancies must be avoided during and within 3 years after aci......
期刊： CLINICAL DRUG INVESTIGATION, 2023; 43 (5)
BackgroundManagement of drug-drug interactions (DDIs) for ensitrelvir, a novel 3-chymotrypsin-like protease inhibitor of SARS-CoV-2 infection is cruci......
